Owlstone Medical Secures Funding To Develop Its Breath Biopsy Technology
The oversubscribed $58m funding round will enable the company to further work on its first-in-class breath biopsy technology, which aims to provide a cheap and convenient screening tool for several diseases.
You may also be interested in...
Following a successful fundraise, Angle is poised to further commercialize its proprietary cell-catching technology for cancer diagnosis
In this month’s Digital Health roundup, Medtech Insight’s Reed Miller talks about iRhythm and Withings’ smartwatches business, Barnaby Pickering reviews digital therapeutics Pear Therapeutics’ restructuring, and Marion Webb presents highlights from her new series on Agetech.
The companies will link Abbott’s blood glucose monitoring devices to WeightWatchers’ smartphone apps and weight loss program.